FDA Grants Priority Review for BEQALZI (Sonrotoclax) NDA220711
The FDA has granted priority review status for BEQALZI, a novel therapy containing sonrotoclax, submitted by Beone Medicines USA.
Asset / Drug
Drug and asset intelligence for BEQALZI with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
BCL-2 Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.